<?xml version="1.0" encoding="UTF-8"?>
<p>BACE-1 inhibitors able to interfere with the inflammation process arose from a thiazolyl-thiadiazine scaffold, which Sagar et al. used to embark with the synthesis of novel MTDLs for AD (
 <bold>49</bold>, 
 <xref ref-type="fig" rid="fig16">Figure 16</xref>) [
 <xref rid="B113" ref-type="bibr">113</xref>]. They were inspired by Verubecestat [
 <xref rid="B114" ref-type="bibr">114</xref>] and other thiadiazine-1,1-dioxide scaffolds acting as BACE-1 inhibitors, along with thiazole-based compounds useful in reducing acute inflammation status, thus potentially able to interfere with COX activity.
</p>
